Functional dyspepsia (FD) is a highly prevalent chronic gastrointestinal (GI) disorder that causes a considerable burden to both the patient and society. Although the etiology and pathogenesis of FD are poorly understood, FD is associated with pathophysiologic abnormalities including delayed gastric emptying (GE), impaired gastric accommodation, and visceral hypersensitivity.
tization before use. The initial body weights of all rats were within the range of 220-250 g. The animals were housed in a regulated environment with a 12-h light/dark cycle. Food and water were given ad libitum, except for the duration of the experimental period. Female Beagle dogs were purchased from Central Lab. Animal Inc. (Seoul, Korea), individually housed in air-conditioned boxes, and given dog food in pellet form (Purina, Dog Chow ® ). All experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of Research Center, Dong-A Pharm. Co., Ltd.
Drug Administration The following drugs were administered to experimental animals: cisapride, domperidone, corydaline, and CTE. All drugs were suspended in 3% HPMC (vehicle) and administered orally in a volume of 5 ml/kg for rats and 1 ml/kg for dogs.
Gastric Emptying GE was measured according to the method of Ozaki and Sukamoto with some modifications. 15) Male Sprague-Dawley rats (220-250 g) were fasted for 18 h with ad libitum access to water. Normal rats were given 2 ml of semi-solid meals by gavages at 60 min following drug administration. After 30 min, animals were sacrificed, and the weights of their stomachs and contents were measured in order to determine GE. GE was calculated using the following equation, as previously described:
GE (%)ϭ[1Ϫweight of test stomach/weight of zero time control stomach]ϫ100
To investigate the effects of CTE and corydaline on GE in normal animals, 80 rats were randomly divided into nine groups (nϭ8-9); four CTE treatment groups (0.3, 1, 3, 10 mg/kg), three corydaline treatment groups (0.1, 1, 10 mg/kg), one reference drug treatment group (cisapride, 10 mg/kg) and one control group (vehicle).
In the next set of experiments, GE was abnormally delayed by administration of apomorphine. Rats were given 2 ml of a semi-solid meal at 60 min following drug administration and simultaneously injected with apomorphine (s.c., 0.05 mg/kg). After 50 min, GE was determined by the method described above. Ninety rats were randomly divided into 11 groups (nϭ8-9); four CTE treatment groups (0.3, 1, 3, 10 mg/kg), three corydaline treatment groups (0.1, 1, 10 mg/kg), two reference drug treatment groups (cisapride, 10 mg/kg; domperidone, 10 mg/kg), one negative control group (vehicle), and one normal group without apomorphine treatment.
Gastrointestinal Transit Gastrointestinal transit was estimated using the geometric center (GC) of non-digestible fluorescein (FITC)-labeled dextran, as previously described. [16] [17] [18] Male Sprague-Dawley rats (220-250 g) were fasted for 18 h with ad libitum access to water. Under ether anesthesia, the median abdomen was opened by a 3-cm midline laparotomy. The small intestine was exteriorized and gently manipulated, then the abdominal muscles and skin were closed with EZ clip applier (Stoelting Co., Wood Dale, IL, U.S.A.). The surgery was completed within 5 min and no analgesic agent was used post-operatively. The drugs were administered orally 4 h post-procedure, and the animals were given a test meal of FITC-dextran by gavages 60 min after drug administration. After 15 min the animals were sacrificed by cervical dislocation, the abdomen opened, and the stomach and small intestine carefully removed. As previously described, 18) the small intestine was divided into ten equal segments (1-10) and the FITC-dextran concentration in each segment was measured using a microplate reader (POLARstar OPTIMA, BMG Labtech, Offenburg, Germany). The GC of the distribution of FITC-dextran was calculated using the following equation, as previously described 13) : GCϭ S (fraction of FITCϪlabeled dextran per segment ϫsegment number)
To determine the effects of CTE on intestinal transit in rats subjected to laparotomy, 80 rats were randomly divided into 10 groups (nϭ8): four laparotomy plus CTE treatment groups (0.3, 1, 3, 10 mg/kg CTE), three laparotomy plus corydaline treatment groups (0.1, 1, 10 mg/kg corydaline), one laparotomy plus reference drug treatment group (cisapride, 10 mg/kg), one sham-operated group (vehicle control), and one normal group.
Gastric Accommodation The effects of CTE on gastric accommodation were examined according to the method of De Ponti et al. with some modification. 19) Five female Beagle dogs (7-9 kg) were operated on under general anesthesia with Tiletamine/Zolazepam (Zoletil ® , Virbac Laboratories, Carros, France; i.v., 10 mg/kg). A chronic gastric fistula was inserted via a midline laparotomy in the larger curvature of the stomach between the glandular portion and forestomach and was exteriorized through the anterior aspect of the abdomen. A recovery period of at least 15 d was allowed before starting the gastric accommodation experiments. Each dog was used only once per week in the experiments. On the morning of the experiments, the dogs were weighed and placed in slings. The gastric fistula was opened and any remaining gastric content was removed with a syringe. We introduced a bag of barostat (Distender Series II TM , G&J Electronics Inc., Toronto, Canada) into the proximal stomach. Animals were administered test drugs and, following an equilibration period, the intrabag pressure was increased by 2-mmHg increments every 3 min, starting from the minimal distending pressure up to 16 mmHg without deflating the barostat bag at each pressure step. Changes in intragastric volume occurring after the administration of CTE or corydaline were automatically measured at the peak of the response. In each experiment, three pressure-volume curves were obtained, allowing a 50-min interval between the end of a distention cycle and the beginning of the subsequent cycle. Volume and pressure data were analyzed using a program in which different parameters were measured and/or calculated (Protocol Plus Deluxe 6.7R, G&J Electronics Inc.).
Data Analysis Results were expressed as meanϮS.E.M. Differences in the data were evaluated using paired t-test for comparison of two groups or one-way ANOVA followed by Dunnett's test for multiple comparisons. A difference was considered significant if pϽ0.05.
RESULTS
In normal rats, GE of semi-solid meals during the 30 min period was 30.9Ϯ1.8, 27.8Ϯ7.9, 44.6Ϯ2.6, and 32.9Ϯ3.7% for 0, 0.1, 1, and 10 mg/kg doses of corydaline, respectively (nϭ8-9 for each dose) (Fig. 1A) . Treatment with CTE also significantly increased GE (pϽ0.05) compared with that of the controls, and the maximal GE effect of CTE was compa-rable to that achieved with 10 mg/kg cisapride. When apomorphine was administered, the GE of a semi-solid meal was markedly delayed by approximately 50% compared with untreated rats (29.8Ϯ2.9% vs. 61.7Ϯ2.9%, pϽ0.05). The delayed GE was rescued by administration of corydaline at a dose of 0.1 mg/kg (44.6Ϯ8.3%), and the maximal GE effect was observed in rats treated with corydaline at dose of 1 mg/kg (45.5Ϯ5.4%, pϽ0.05) (Fig. 1B) . Treatment with CTE at a dose of 1 mg/kg (57.7Ϯ4.4%) significantly restored the delayed GE to a near normal level. These results suggest that corydaline may accelerate GE under normal conditions, and furthermore, can correct the abnormal delay in GE that is induced by apomorphine.
Laparotomy with mild intestinal manipulation produced a significant delay in GI transit (GCϭ2.56Ϯ0.09, nϭ8, pϽ0.05) compared with the normal group (GCϭ3.83Ϯ0. 19, nϭ8) . CTE was associated with normalization of laparotomy-induced delayed GI transit at doses of 0.3 mg/kg (GCϭ3.48Ϯ0.24, nϭ8, pϽ0.05) and 1 mg/kg (GCϭ3.87Ϯ 0.09, nϭ8, pϽ0.05), results comparable to those obtained with cisapride (GCϭ3.62Ϯ0.09, nϭ8, pϽ0.05) (Fig. 2) .
The effects of corydaline and CTE on gastric accommodation were assessed in Beagle dogs using a barostat. The first distension cycle was used to unfold the intragastric bag, and the recorded values were discarded. The second distension cycle was used as a control. For the third distention cycle, corydaline was gavaged 40 min prior to initiating the distension cycle. Baseline gastric volumes were measured at 2 mmHg were 16Ϯ9 ml and 13Ϯ3 ml before and after corydaline treatment, respectively (Table 1) . Corydaline (1 mg/kg) was associated with relaxation of the proximal stomach. With the use of the exponential model, a significant shift in the pressure-volume curve was observed with corydaline compared to control, resulting in a large increase in slope at 1 / 2 P max by 19.06 ml/mmHg (vs. 13.81, pϽ0.01), and the volume at 1 / 2 P max by 69Ϯ12 ml (vs. 59Ϯ18). There were signifi-960 Vol. 33, No. 6
Fig. 1. Effect of Corydaline on Gastric Emptying (GE)
After 18 h of fasting, animals (nϭ8-9 for each group) were orally treated with Corydalis tuber extract (CTE), corydaline, cisapride (Cisa), and domperidone (Dom) at the indicated dosages, or with 3% HPMC as a vehicle (Con). (A) GE in normal rats; (B) GE in the apomorphine-induced delayed GE model. GE was calculated as described in Materials and Methods. Values are the meanϮS.E.M. of three experiments.
* pϽ0.05 vs. control (one way ANOVA with post-hoc Dunnett's test).
Fig. 2. Effect of Corydaline on Gastrointestinal Transit in the Laparotomy-Induced Delayed Model
After 18 h of fasting, animals (nϭ8 for each group) were orally treated with CTE, corydaline, and cisapride (Cisa) at the indicated dosages or with 3% HPMC as a vehicle (Con). The geometric center was calculated as described in Materials and Methods. Values are the meanϮS.E.M. of three experiments. * pϽ0.05 vs. control (one way ANOVA with post-hoc Dunnett's test). a) V is volume (in ml), V 0 is theoretical volume when Pϭ0 mmHg, P is pressure (in mmHg), and k 1 is the rate constant. The overall fit for each curve was summarized as an r cant differences between the corydaline treated and control groups in the volume at pressures of 8 and 10 mmHg (pϽ0.05 and pϽ0.01, respectively) (Fig. 3) . These results suggest that corydaline may induce gastric relaxation and increase gastric compliance.
DISCUSSION
There is no single therapy available that is capable of providing relief to the majority of FD patients due to the pathophysiological heterogeneity of the disease. There are currently several relevant drugs marketed or under development, including prokinetics and fundic relaxant drugs. Prokinetics, such as cisapride and mosapride, are a group of drugs that stimulate smooth muscle contraction to enhance GE and intestinal transit. 20, 21) Recent studies have demonstrated that impaired gastric accommodation in FD may contribute to symptom generation. 22) Matsueda et al. showed that acotiamide, a fundus-relaxing drug that acts via blockade of the M1/M2 muscarinic receptor, significantly improves the symptoms of FD and is more effective in reducing symptoms in patients with the postprandial distress syndrome of FD than in patients with epigastric pain syndrome. 23) We previously demonstrated that DA-9701, a multi-herbal extract formulated from Pharbitidis semen and Corydalis tuber that is currently in clinical trials for the treatment of FD, is a potential safe and effective therapeutic agent for patients with abnormalities in GI motor function. 13) Choi et al. showed that the pacemaker currents in interstitial cells of Cajal (ICC) are cellular and molecular targets underlying the effects of DA-9701 on GI motor function by means of intracellular mobilization of Ca 2ϩ through phospholipase C.
24)
As a representative compound extract of Corydalis tubers, corydaline can significantly enhance GI motor functions that accelerate GE and GI transit as well as gastric accommodation. GE and GI transits are well-established models used in numerous studies to evaluate prokinetics. Corydaline enhanced GE in normal rats with an effective dose of 1 mg/kg, much lower than that of conventional prokinetics. Following treatment with corydaline, GE increased from 30.9Ϯ1.8 to 44.6Ϯ2.6%, comparable to treatment with cisapride (50.9Ϯ5.5%). When apomorphine was administered, GE was reduced to 29.8Ϯ2.9% compared to the normal group (61.7Ϯ2.9%). Treatment with corydaline at a dose of 1 mg/kg significantly abrogated the delayed GE induced by apomorphine (45.5Ϯ5.4%, pϽ0.05). Apomorphine is known to inhibit GE by acting as a dopamine agonist, and domperidone (D 2 receptor antagonist) and cisapride (5-HT 3 antagonist and 5-HT 4 agonist) also accelerated delayed GE in this model (62.4Ϯ2.6, 65.6Ϯ3.0%, respectively).
CTE possesses moderate affinity for D 2 , 5-HT 1B , and 5-HT 4 receptors (K i ϭ0.2, 6.3, 7.6 mg/ml, respectively). In our previous studies, CTE produced 5-HT 4 receptor-mediated relaxation of the rat esophagus (EC 50 ϭ12.9 mg/ml) and contraction of the guinea pig colon (EC 50 ϭ1.4 mg/ml). It was suggested that CTE and its main component, corydaline, contributed in part to the ameliorative effect on the delayed GE induced by apomorphine, and that the action mechanism of CTE and corydaline may be related to serotonergic or dopaminergic activity.
The present study showed a mild improvement in delayed GI transit by treatment with corydaline. Delayed GI transit induced by laparotomy with mild intestinal manipulation was partially recovered with administration of corydaline: the GC was increased from 2.56 to 3.12 by corydaline compared with a GC of 3.83 in normal rats. It therefore appears that corydaline is not the only component of CTE capable of enhancing GI motor function. The effects of the herbal extract appear to be additive with a combination of various ingredients; thus corydaline may be the primary, but not the sole, active constituent responsible for the prokinetic effects of CTE.
CTE and corydaline accelerated GE for both normal and delayed GE, and restored delayed small bowel transit with bell-shaped dose-response curves. Bell-shaped dose-response curves have been reported in experimental animal models when evaluating the therapeutic efficacy of prokinetic drugs such as cisapride, itopride, and tegaserod. [25] [26] [27] The reason for these dose-dependent effects of CTE and corydaline on GI motility is not clear, although there are several Fig. 3 . Effect of Corydaline on Gastric Accommodation in Beagle Dogs possible explanations. First, the dose range used may be at the upper end of the dose-response curve. Second, the drugs may not act via a specific receptor-mediated mechanism enhancing GI motor activity. Third, the drug may bind to the activation site or the inhibition site on the receptor with different affinity. 28) Finally, the drug may act at receptors other than D 2 receptors at higher doses, thereby inhibiting its potential to enhance GI motility or obscuring its prokinetic effects. It has been reported that several receptors are associated with GI disorders. 29) Dopamine decreases the tone and motility of the GI tract, and dopamine antagonists, such as sulpiride, domperidone, and metoclopramide, enhance the peristaltic contractions of the esophageal body, increase the muscle tone of the lower esophageal sphincter, and stimulate gastrointestinal motor activity. 30, 31) It appears that stimulation of the 5-HT 1B receptor has a relaxation effect on gastric tone in dogs since the antimigraine 5-HT 1B/D receptor agonist sumatriptan induces an immediate gastric relaxation and gastric accommodation mediated by 5-HT 1B receptors. 19) The gastric barostat technique is the most common method for measuring gastric compliance and accommodation in both humans and animals. Corydaline induced gastric accommodation at a dose of 1 mg/kg but had no measurable effect on gastric tone. The slope at 1 / 2 P max of the pressurevolume curve, which provides an estimation of gastric compliance, was significantly increased following corydaline treatment ( pϽ0.01). Corydaline had a moderate effect on the pressure-volume curve that fitted the exponential model better than the linear model. It has been suggested that an exponential equation fits the concept of adaptive accommodation to a distending stimulus and therefore corydaline may facilitate the rapid relaxation of the gastric fundus to accept large meals with only a minimal increase in pressure. Nevertheless, it is unclear which effect of corydaline contributed to its efficacy, as the abilities to enhance GE and to facilitate gastric accommodation have both been identified as potentially relevant. 29) Previous studies suggested that the activity of CTE and its main component, corydaline, may be related to the 5-HT 4 receptor because the 5-HT 4 receptor agonists cisapride and tegaserod are known to accelerate GE and small bowel transit and enhance gastric accommodation in humans. [32] [33] [34] [35] [36] Furthermore, corydaline has weak affinity for the 5-HT 1A , 5-HT 1B , and non-selective 5-HT 1 receptor subtypes (pK i Ͻ5; data not shown), thus excluding the 5-HT 1 receptors from the gastric-relaxing effect. Further study is necessary to clarify the mechanisms of action of corydaline.
In summary, the current study provides the first in vivo evidence that corydaline is an active compound of Corydalis tuber potentially responsible for improvement of GI motor function.
